| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| DeLong Mark Jeffrey | Chief Business & Strat Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM | /s/ David Watson, attorney-in-fact for Mark DeLong | 21 Jan 2026 | 0001856078 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLS | Common Stock | Sale | $26,404 | -1,334 | -1.6% | $19.79 | 81,724 | 20 Jan 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026. |